Guinan P D, McKiel C, Sundar B, Veith R, Dubin A, Ablin R J
Natl Cancer Inst Monogr. 1978 Dec(49):225-9.
The diagnostic value of the CEA test was evaluated in 2,029 blood and urine samples from 308 patients with urologic cancer, 13 with nonurologic cancer, 20 urologic patients with nonmalignant disease, and in 30 controls. The blood CEA test was positive in 50% of the patients with active urologic cancer and in 35% of those with inactive cancer. The urine CEA test was elevated only in patients with active bladder cancer, but most of these had concurrently infected urines. At the present time, the CEA test does not reflect the accuracy necessary for an acceptable diagnostic test for the detection of urologic cancer.
对308例泌尿系统癌症患者、13例非泌尿系统癌症患者、20例患有非恶性疾病的泌尿系统患者以及30名对照者的2029份血液和尿液样本进行了癌胚抗原(CEA)检测的诊断价值评估。血液CEA检测在50%的活动性泌尿系统癌症患者和35%的非活动性癌症患者中呈阳性。尿液CEA检测仅在活动性膀胱癌患者中升高,但其中大多数患者同时伴有尿液感染。目前,CEA检测对于检测泌尿系统癌症而言,未达到可接受的诊断检测所需的准确性。